Rafael Henry-Venson

Dr. Rafael Henry-Venson

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
AWAstrid Wiens
Astrid Wiens
RHRafael Henry-Venson
Rafael Henry-Venson
CCCassyano J. Correr
Cassyano J. Correr
MOMichel Fleith Otuki
Michel Fleith Otuki
RPRoberto Pontarolo
Roberto Pontarolo

20 December 2011 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
AMAna Carolina Melchiors
Ana Carolina Melchiors
CCCassyano Januário Correr
Cassyano Januário Correr
RHRafael Henry-Venson
Rafael Henry-Venson
RPRoberto Pontarolo
Roberto Pontarolo


26 August 2009 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AWAstrid Wiens
Astrid Wiens
CCCassyano Januário Correr
Cassyano Januário Correr
RHRafael Henry-Venson
Rafael Henry-Venson
MOMichel Fleith Otuki
Michel Fleith Otuki
RPRoberto Pontarolo
Roberto Pontarolo

1 December 2009 in Brazilian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
CCCassyano Januário Correr
Cassyano Januário Correr
RPRoberto Pontarolo
Roberto Pontarolo
RSRodrigo Augusto de Paula e Souza
Rodrigo Augusto de Paula e Souza
RHRafael Henry-Venson
Rafael Henry-Venson
AMAna Carolina Melchiors
Ana Carolina Melchiors
AWAstrid Wiens
Astrid Wiens
The aim is to evaluate the humanistic outcomes in type 2 diabetic patients by the adoption of pharmacotherapy follow-up in community pharmacies. Controlled, non-randomized, 12-months trial; n=161 patients distributed into control and intervention groups; 6 community pharmacies involved, all in the Curitiba city region, in the state of Paraná were used. The health-related quality of life (HRQoL) and the satisfaction index were determined using both the DQOL assessment tool, which measures HRQoL, and the satisfaction evaluation tool (QSSF). Interventions on 119 negative therapeutic outcomes were done (2.3/patient [SD=1.6]); the most commonly found problems were related to ineffectiveness of pharmacotherapy (68.1%). The Intervention-Group showed a significant improvement in HRQoL compared with the Control Group (0.08 vs -0.01, respectively; p=0.036). Satisfaction and impact domains presented the most significant improvement (0.13 vs 0.00 [p=0.030] and 0.07 vs -0.04 [p=0.033], respectively). After adjusting for baseline variables, the difference in improvement scores between groups on the QSSF was attributed to the allocation of patients in the intervention group. Pharmacotherapy follow-up of type 2 diabetic patients in community pharmacies can improve the HRQoL and satisfaction of patients.

8 September 2009 in Scandinavian Journal of Immunology
Verified
Journal Article
Closed access
PDF file
AWAstrid Wiens
Astrid Wiens
CCCassyano Januario Correr
Cassyano Januario Correr
RPRoberto Pontarolo
Roberto Pontarolo
RHRafael Henry-Venson
Rafael Henry-Venson
JQJuliana Vasconcelos Quinalha
Juliana Vasconcelos Quinalha
MOMichel Fleith Otuki
Michel Fleith Otuki